Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2005, Issue 3, Pages 287-290
http://dx.doi.org/10.1155/JBB.2005.287
Research article

Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis

1Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, IL 60612, USA
2Department of Biochemistry, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
3Department of Urology, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
4Department of Urology, University of Illinois at Chicago, Chicago, IL 60612, USA

Received 26 May 2004; Revised 27 July 2004; Accepted 9 October 2004

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [10 citations]

The following is the list of published articles that have cited the current article.

  • Awatef Ben Jemaa, Yosra Bouraoui, Sataa Sallami, Ahmed Banasr, Nawfel Ben Rais, Latifa Ouertani, Yassin Nouira, Ali Horchani, and Ridha Oueslati, “Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies,” Journal Of Experimental & Clinical Cancer Research, vol. 29, 2010. View at Publisher · View at Google Scholar
  • Shawn M. Hillier, Ashley M. Kern, Kevin P. Maresca, John C. Marquis, William C. Eckelman, John L. Joyal, and John W. Babich, “I-123-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy,” Journal Of Nuclear Medicine, vol. 52, no. 7, pp. 1087–1093, 2011. View at Publisher · View at Google Scholar
  • Zeyu Xiao, Jillian Frieder, Benjamin A. Teply, and Omid C. Farokhzad, “Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy,” Drug Delivery in Oncology, pp. 1263–1281, 2011. View at Publisher · View at Google Scholar
  • Mingfeng Zhang, Fengju Song, David J. Hunter, Abrar A. Qureshi, and Jiali Han, “Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer,” Cancer Epidemiology Biomarkers & Prevention, vol. 22, no. 12, pp. 2354–2363, 2013. View at Publisher · View at Google Scholar
  • Robyn Bradbury, Wen G Jiang, and Yu-Xin Cui, “The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers,” Biomarkers in Medicine, 2015. View at Publisher · View at Google Scholar
  • Mike Sathekge, Thabo Lengana, Moshe Modiselle, Mariza Vorster, JanRijn Zeevaart, Alex Maes, Thomas Ebenhan, and Christophe Van de Wiele, “68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients,” European Journal of Nuclear Medicine and Molecular Imaging, 2016. View at Publisher · View at Google Scholar
  • Saima Nawaz, Gregory E.D. Mullen, Philip J. Blower, and James R. Ballinger, “A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen,” Nuclear Medicine Communications, vol. 38, no. 8, pp. 666–671, 2017. View at Publisher · View at Google Scholar
  • Mike Sathekge, Thabo Lengana, Alex Maes, Mariza Vorster, JanRijn Zeevaart, Ismaheel Lawal, Thomas Ebenhan, and Christophe Van de Wiele, “68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans,” European Journal of Nuclear Medicine and Molecular Imaging, 2017. View at Publisher · View at Google Scholar
  • Priyanka Verma, Gaurav Malhotra, Atul Goel, Sutapa Rakshit, Ashok Chandak, Rupal Chedda, Sharmila Banerjee, and Ramesh V. Asopa, “Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients,” Clinical Nuclear Medicine, vol. 44, no. 5, pp. e318–e322, 2019. View at Publisher · View at Google Scholar
  • Guillaume Chaussé, Gad Abikhzer, Stephan Probst, and Jerome Laufer, “ Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18 F-DCFPyL PET/CT ,” Clinical Nuclear Medicine, vol. 44, no. 3, pp. 255–256, 2019. View at Publisher · View at Google Scholar